Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(02): 123-129
DOI: 10.1055/s-0041-1733823
Original Article

Persistent Antibody Responses to SARS-CoV-2 Infection in Cancer Patients: A Single-Center Retrospective Observational Study

Amit Agarwal
1   Department of Medical Oncology, Dr BL Kapur Super Specialty Hospital, New Delhi, India
,
Saphalta Baghmar
1   Department of Medical Oncology, Dr BL Kapur Super Specialty Hospital, New Delhi, India
,
Suhail Qureshi
1   Department of Medical Oncology, Dr BL Kapur Super Specialty Hospital, New Delhi, India
,
Aseem Khurana
1   Department of Medical Oncology, Dr BL Kapur Super Specialty Hospital, New Delhi, India
,
Rasika Setia
2   Department of Transfusion Medicine, Dr BL Kapur Super Specialty Hospital, New Delhi, India
,
Maroof Ahmad Khan
3   Department of Bio-Statistics, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi, India
,
Purabi Barman
4   Department of Clinical Microbiology, Dr BL Kapur Super Specialty Hospital, New Delhi, India
,
Raj Kumar Kapoor
5   Department of Clinical Biochemistry, Dr BL Kapur Super Specialty Hospital, New Delhi, India
,
Navneeth Reddy Hasthavaram
1   Department of Medical Oncology, Dr BL Kapur Super Specialty Hospital, New Delhi, India
,
Ramesh Kumar
1   Department of Medical Oncology, Dr BL Kapur Super Specialty Hospital, New Delhi, India
,
Navdeep Singh
1   Department of Medical Oncology, Dr BL Kapur Super Specialty Hospital, New Delhi, India
,
Aditya Sarin
1   Department of Medical Oncology, Dr BL Kapur Super Specialty Hospital, New Delhi, India
,
Anil Handoo
6   Research & Continuing Education (AARCE), Dr BL Kapur Super Specialty Hospital, New Delhi, India
› Author Affiliations Funding Not applicable.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Introduction There is limited literature available regarding the prevalence and durability of immune response to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19) in cancer patients.

Objective The aim of this study was to analyze the seroconversion rate in cancer patients recovered from SARS-CoV-2 infection.

Materials and Methods We retrospectively analyzed antibody levels and seroconversion rates in serum samples from 135 cancer patients who had recovered from SARS-CoV-2 infection. Chemiluminescent immunoassay using Roche Cobas e801 analyzer (Roche Diagnostics, Rotkreuz, Switzerland) was performed to identify Pan Ig antibody against nucleocapsid antigen. Reports of first, third, and sixth month were analyzed. Seroconversion was also compared with health-care workers (HCW) of our institute who had recovered from COVID-19 infection.

Results Seroconversion rate in cancer patients was 81.2% at 1 month, 95% at 3 months, and 94.6% at 6 months post reverse transcriptase–polymerase chain reaction positivity. There was no difference in seroconversion rate among different age groups, gender, comorbidities, severity of COVID-19 symptoms, cancer disease status, and treatment with chemotherapy. Seroconversion rate in cancer patients is comparable to HCW (90.4 vs. 96%, p = 0.82) and is durable.

Conclusion Humoral response to COVID-19 infection in cancer patients is comparable to general population and sustained. Such responses suggest that cancer patients are likely to benefit from COVID-19 vaccination.

Keywords

COVID-19 - SARS-CoV-2 - anti-SARS-CoV-2-antibody - cancer - seroconversion - chemotherapy - India

Supplementary Material



Publication History

Article published online:
06 August 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 COVID-19. Coronavirus Pandemic. https://www.worldometers info/coronavirus/. Accessed July 12, 2021
  • 2 Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21 (03) 335-337
    CrossrefPubMedGoogle Scholar
  • 3 Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020; 323 (18) 1775-1776
    PubMedGoogle Scholar
  • 4 Vabret N, Britton GJ, Gruber C. et al. Sinai Immunology Review Project. Immunology of COVID-19: current state of the science. Immunity 2020; 52 (06) 910-941
    CrossrefPubMedGoogle Scholar
  • 5 Zhao J, Yuan Q, Wang H. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis 2020; 71 (16) 2027-2034
    CrossrefPubMedGoogle Scholar
  • 6 Pollán M, Pérez-Gómez B, Pastor-Barriuso R. et al. ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020; 396 (10250) 535-544
    CrossrefPubMedGoogle Scholar
  • 7 Long Q-X, Tang X-J, Shi Q-L. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26 (08) 1200-1204
    CrossrefPubMedGoogle Scholar
  • 8 WardH, CookeGS, AtchisonC, et al. Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. The Lancet Regional Health - Europe, 2021;4:100098. ISSN 2666-7762. Available at: https://doi.org/10.1016/j.lanepe.2021.100098
  • 9 Bölke E, Matuschek C, Fischer JC. Loss of anti-SARS-CoV-2 antibodies in mild Covid-19. N Engl J Med 2020; 383 (17) 1694-1695
    CrossrefPubMedGoogle Scholar
  • 10 Ibarrondo FJ, Fulcher JA, Goodman-Meza D. et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. N Engl J Med 2020; 383 (11) 1085-1087
    CrossrefPubMedGoogle Scholar
  • 11 Gudbjartsson DF, Norddahl GL, Melsted P. et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med 2020; 383 (18) 1724-1734
    CrossrefPubMedGoogle Scholar
  • 12 prpt . Wajnberg A, Amanat F, Firpo A, et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. July 17, 2020 (https://www. medrxiv. org/ content/ 10. 1101/ 2020. 07. 14. 20151126v1)./prpt
  • 13 Solodky ML, Galvez C, Russias B, et al. Lower detection rates of SARS-COV1 antibodies in cancer patients vs healthcare workers after symptomatic COVID-19. Annals of Oncology. doi:10.1016/j.annonc.2020.04.475.} DOI: https://doi.org/10.21203/rs.3.rs71560/v1}/prpt
  • 14 Liu T, Zeng G, Tao H. et al. COVID-19 in Cancer Patients Research Group. Low prevalence of IgG antibodies to SARS-CoV-2 in cancer patients with COVID-19. Int J Cancer 2020; 147 (11) 3267-3269
    CrossrefPubMedGoogle Scholar
  • 15 Berglund A, Willén L, Grödeberg L, Skattum L, Hagberg H, Pauksens K. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncol 2014; 53 (09) 1212-1220
    CrossrefPubMedGoogle Scholar
  • 16 Nordøy T, Aaberge IS, Husebekk A. et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002; 19 (02) 71-78
    CrossrefPubMedGoogle Scholar
  • 17 Polack FP, Thomas SJ, Kitchin N. et al. C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383 (27) 2603-2615
    CrossrefPubMedGoogle Scholar
  • 18 Folegatti PM, Ewer KJ, Aley PK. et al. Oxford COVID Vaccine Trial Group. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020; 396 (10/249) 467-478
    CrossrefPubMedGoogle Scholar
  • 19 Jackson LA, Anderson EJ, Rouphael NG. et al. mRNA-1273 Study Group. An mRNA vaccine against SARS-CoV-2 - preliminary Report. N Engl J Med 2020; 383 (20) 1920-1931
    CrossrefPubMedGoogle Scholar
  • 20 World Health Organization. Clinical management of COVID-19: interim guidance. May 27, 2020.
  • 21 https://www.icmr.gov.in/pdf/covid/labs/2_SOP_for_Confirmatory_Assay_for_2019_nCoV.pdf. Accessed July 12, 2021
  • 22 Roche. Elecsys® Anti-SARS-CoV-2. Package Insert 2020–07, V3.0; Material Numbers 09203095190 and 09203079190. US Food and Drug Administration https://www.fda.gov/media/137605/download. Accessed July 12, 2021
  • 23 SetiaR, DograM, HandooA, et al. Performance Evaluation: Four Chemiluminescent SARS-Cov-2 Immunoassays and Rapid-Card Test in Mild Disease and Seroprevalence of SARS CoV-2 in Frontline Healthcare Workers. Int Blood Res Rev 2021;12(3):9-22. Available at: https://doi.org/10.9734/ibrr/2021/v12i330151
  • 24 Muench P, Jochum S, Wenderoth V. et al. Development and validation of the Elecsys Anti-SARS-CoV-2 immunoassay as a highly specific tool for determining past exposure to SARS-CoV-2. J Clin Microbiol 2020; 58 (10) e01694-e20
    CrossrefPubMedGoogle Scholar
  • 25 Nie J, Li Q, Wu J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect 2020; 9 (01) 680-686
    CrossrefPubMedGoogle Scholar
  • 26 Lei C, Qian K, Li T. et al. Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. Nat Commun 2020; 11 (01) 2070
    CrossrefPubMedGoogle Scholar
  • 27 Lumley SF, O’Donnell D, Stoesser NE. et al. Oxford University Hospitals Staff Testing Group. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med 2021; 384 (06) 533-540 DOI: 10.1056/NEJMoa2034545.
    CrossrefPubMedGoogle Scholar
  • 28 prpt . Harvey RA, Rassen JA, Kabelac CA, et al. Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infection. medRxiv 2020; https://orcid.org/0000-0001-9372-9869/prpt
  • 29 Houot R, Levy R, Cartron G, Armand P. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?. Eur J Cancer 2020; 136: 4-6
    CrossrefPubMedGoogle Scholar